Yanxia Li is a notable inventor based in Floral Park, NY (US). He has made significant contributions to the field of biotechnology, particularly in the development of antibodies. His work focuses on creating innovative solutions for treating various types of cancer.

Latest Patents

Yanxia Li holds a patent for "Antibodies against CSF-1R." This invention provides a human antibody that binds human CSF-1R with high affinity. The antibodies developed through this invention have significant advantages over existing antibodies by being multifunctional. They inhibit signaling of CSF-1R, internalize and induce CSF-1R degradation, and stimulate antibody-dependent cellular cytotoxicity (ADCC) in cells, including tumors, macrophages, and monocytes. These antibodies have shown effectiveness in treating leukemia, breast, endometrial, and prostate cancer, either alone or in combination with treatments such as docetaxel, paclitaxel, Herceptin®, or doxorubicin.

Career Highlights

Yanxia Li is associated with Imclone LLC, a company known for its focus on developing innovative cancer therapies. His work at Imclone LLC has been instrumental in advancing the understanding and treatment of cancer through antibody technology.

Collaborations

Yanxia Li collaborates with Jacqueline Francoise Doody, who is also a key figure in the field. Their partnership exemplifies the collaborative spirit in scientific research and innovation.

Conclusion

Yanxia Li's contributions to antibody development represent a significant advancement in cancer treatment. His innovative work continues to pave the way for new therapeutic options in oncology.

Profile summary based on public USPTO records.